E³ - ECR Master Class: Breast
E³ 2226 - Current applications in imaging-tailored therapy
Lectures
1
Chairperson's introduction
05:00Thomas H. Helbich, Vienna / AT
2
Image adjusted post-NAC treatment and therapy
15:00Ritse Maarten Mann, Nijmegen / NL
3
Update on image-guided therapy
15:00Alexandra Athanasiou, Athens / GR
4
Image-guided de-escalation of treatment: the PROSPECT trial paradigm shift
15:00Bruce Mann, Parkville / AU
5
Panel discussion: How does surgery look like in the near future?
10:00Panel discussion: How does surgery look like in the near future?
5 min
Chairperson's introduction
Thomas H. Helbich, Vienna / Austria
15 min
Image adjusted post-NAC treatment and therapy
Ritse Maarten Mann, Nijmegen / Netherlands
1. To understand MRI's interpretation and clinical applications in post-NAC treatment.
2. To list causes of over- and underestimation of residual disease at MRI.
3. To discuss the advantages and limitations of different post-NAC therapy.
2. To list causes of over- and underestimation of residual disease at MRI.
3. To discuss the advantages and limitations of different post-NAC therapy.
15 min
Update on image-guided therapy
Alexandra Athanasiou, Athens / Greece
1. To understand the role of breast imaging in image-guided therapy.
2. To present updates on current techniques.
3. To understand patient selection criteria and eligibility for image-guided therapy.
4. To discuss future options.
2. To present updates on current techniques.
3. To understand patient selection criteria and eligibility for image-guided therapy.
4. To discuss future options.
15 min
Image-guided de-escalation of treatment: the PROSPECT trial paradigm shift
Bruce Mann, Parkville / Australia
1. To consider the current treatment protocols for the omission of radiotherapy in early breast cancer (EBC).
2. To reflect on the nature of EBC, including the existence and potential importance of undiagnosed cancers occult on conventional imaging.
3. To differentiate minimal/mild BPE from moderate/marked BPE on breast MRI and predict how it will affect the identification of synchronous occult cancers, thereby impacting the ability to de-escalate treatment.
4. To adapt existing knowledge of local staging of breast cancers with MRI to enable identification of unifocal EBCs for which radiotherapy may be safely omitted and multifocal/centric disease for treatment intensification.
2. To reflect on the nature of EBC, including the existence and potential importance of undiagnosed cancers occult on conventional imaging.
3. To differentiate minimal/mild BPE from moderate/marked BPE on breast MRI and predict how it will affect the identification of synchronous occult cancers, thereby impacting the ability to de-escalate treatment.
4. To adapt existing knowledge of local staging of breast cancers with MRI to enable identification of unifocal EBCs for which radiotherapy may be safely omitted and multifocal/centric disease for treatment intensification.
10 min
Panel discussion: How does surgery look like in the near future?